AbCellera says Phase 2 trial shows ABCL635 cuts menopausal hot flashes after single dose

• AbCellera reported positive top-line Phase 2 results from its Phase 1/2 trial of ABCL635 for menopausal hot flashes.
• Results have been presented, showing a meaningful reduction in hot-flash frequency and severity versus placebo following a single dose.
• Trial readout also indicated improvements in sleep and patient-reported overall change.
• Safety profile appeared favorable over four weeks, with no serious events reported.
• An investor conference call is scheduled for today at 7:30 a.m. ET to discuss the data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608100700BIZWIRE_USPR_____20260810_BW931321) on August 10, 2026, and is solely responsible for the information contained therein.